The effect of rutaecarpine on improving fatty liver and osteoporosis in MAFLD mice
10.16438/j.0513-4870.2024-0907
- VernacularTitle:吴茱萸次碱改善MAFLD小鼠脂肪肝和骨质疏松的作用
- Author:
Yu-hao ZHANG
1
;
Yi-ning LI
1
;
Xin-hai JIANG
2
;
Wei-zhi WANG
1
;
Shun-wang LI
1
;
Ren SHENG
1
;
Li-juan LEI
1
;
Yu-yan ZHANG
1
;
Jing-rui WANG
1
;
Xin-wei WEI
1
;
Yan-ni XU
1
;
Yan LIN
3
;
Lin TANG
4
;
Shu-yi SI
1
Author Information
1. Key Laboratory of Biotechnology for Microbial Drugs, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, National Center for Screening Novel Microbial Drugs, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing
2. Key Laboratory of Biotechnology for Microbial Drugs, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, National Center for Screening Novel Microbial Drugs, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing; Beijing Ditan Hospital, Capital Medical University, Beijing
3. Beijing Institute of Chinese Medicine, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing
4. China Medico Corporation, Tianjin
- Publication Type:Research Article
- Keywords:
rutaecarpine;
nonalcoholic fatty liver disease;
metabolic-associated fatty liver disease;
osteoporosis;
bone metabolism
- From:
Acta Pharmaceutica Sinica
2025;60(1):141-149
- CountryChina
- Language:Chinese
-
Abstract:
Metabolic-associated fatty liver disease (MAFLD) and osteoporosis (OP) are two very common metabolic diseases. A growing body of experimental evidence supports a pathophysiological link between MAFLD and OP. MAFLD is often associated with the development of OP. Rutaecarpine (RUT) is one of the main active components of Chinese medicine Euodiae Fructus. Our previous studies have demonstrated that RUT has lipid-lowering, anti-inflammatory and anti-atherosclerotic effects, and can improve the OP of rats. However, whether RUT can improve both fatty liver and OP symptoms of MAFLD mice at the same time remains to be investigated. In this study, we used C57BL/6 mice fed a high-fat diet (HFD) for 4 months to construct a MAFLD model, and gave the mice a low dose (5 mg·kg-1) and a high dose (15 mg·kg-1) of RUT by gavage for 4 weeks. The effects of RUT on liver steatosis and bone metabolism were then evaluated at the end of the experiment [this experiment was approved by the Experimental Animal Ethics Committee of Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (approval number: IMB-20190124D303)]. The results showed that RUT treatment significantly reduced hepatic steatosis and lipid accumulation, and significantly reduced bone loss and promoted bone formation. In summary, this study shows that RUT has an effect of improving fatty liver and OP in MAFLD mice.
